Financial Engines Advisors L.l.c. buys $14,080,572 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Financial Engines Advisors L.l.c. scooped up 49,365 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 10, 2016. The investment management firm now holds a total of 227,106 shares of AbbVie Inc which is valued at $14,080,572.AbbVie Inc makes up approximately 11.84% of Financial Engines Advisors L.l.c.’s portfolio.

Other Hedge Funds, Including , Investment Partners Ltd Oh Adv added ABBV to its portfolio by purchasing 11,152 company shares during the most recent quarter which is valued at $691,424. AbbVie Inc makes up approx 0.44% of Investment Partners Ltd Oh Adv’s portfolio.Nationwide Fund Advisors boosted its stake in ABBV in the latest quarter, The investment management firm added 612,504 additional shares and now holds a total of 1,523,213 shares of AbbVie Inc which is valued at $95,216,045. AbbVie Inc makes up approx 0.41% of Nationwide Fund Advisors’s portfolio.Annex Advisory Services boosted its stake in ABBV in the latest quarter, The investment management firm added 1,491 additional shares and now holds a total of 24,600 shares of AbbVie Inc which is valued at $1,537,746. AbbVie Inc makes up approx 0.44% of Annex Advisory Services’s portfolio.Alexandria Capital boosted its stake in ABBV in the latest quarter, The investment management firm added 16 additional shares and now holds a total of 4,529 shares of AbbVie Inc which is valued at $276,269. AbbVie Inc makes up approx 0.05% of Alexandria Capital’s portfolio.

AbbVie Inc opened for trading at $61.91 and hit $62.62 on the upside on Monday, eventually ending the session at $62.45, with a gain of 0.73% or 0.45 points. The heightened volatility saw the trading volume jump to 67,07,435 shares. Company has a market cap of $101,004 M.

On the company’s financial health, AbbVie Inc reported $1.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.14. The company had revenue of $5958.00 million for the quarter, compared to analysts expectations of $5978.41 million. The company’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. Societe Generale Initiated AbbVie Inc on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $47.Deutsche Bank Initiated AbbVie Inc on Mar 15, 2016 to “Hold”, Price Target of the shares are set at $63.AbbVie Inc was Upgraded by Citigroup to ” Buy” on Feb 23, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.